Foster City · Series B–Late Stage · 17 people tracked
Investment thesis
Gilead's research and development approach centers on pursuing transformative medicines and cures across three therapeutic areas: virology, oncology and inflammation. Drawing on a 35-plus-year track record, the company identifies best-in-class molecules, biologics, cell therapies and combinations and advances them quickly. It has helped turn public health challenges such as HIV and hepatitis C into manageable or curable conditions, and is developing therapies across viral hepatitis, SARS-CoV-2 and potential pandemic viruses. In oncology it seeks treatments offering long-term remission and cures, while in immunology it targets next-generation therapies for inflammatory and fibrotic diseases. The company set an ambition in 2019 to deliver 10-plus transformative therapies by 2030.
Source: firm website, verified Aug 16, 2026.
Team · 17 people
from the firm's websiteWhat they invest in
from 2 of 2 portfolio companiesBiotech ×2AI & Machine Learning ×1Healthtech ×1
HQs:United States×1
Investments · 2 tracked
founders shown can be your intro pathTizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)Courtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersMPM BioImpactAbingworthAstellas Venture Management LLCLightstone Ventures
BiotechPhiladelphia, US
Anne Chew(Director and President)
BoardKevin Mahoney(Director)
Co-investorsAndreessen HorowitzLAVLilly Asia VenturesMilitia Hill VenturesKleiner Perkins
Portfolio news
latest coverage across their companiesTmunity Therapeutics · whyy.org · Jul 10, 2025
Frequently asked questions
- What stage does Gilead Sciences invest at?
- Gilead Sciences invests at the Series B, Series C, Late Stage stages.
- What sectors does Gilead Sciences focus on?
- Gilead Sciences focuses on Advanced Manufacturing, Biotech, Healthtech, SaaS.
- Where is Gilead Sciences located?
- Gilead Sciences is headquartered in Foster City, US.
Media · Podcasts & interviews
featuring the teamGilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
CNBC Television · Daniel O’Day
Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.
PhRMA · Daniel O’Day
Watch CNBC's full interview with Gilead Sciences chairman and CEO Daniel O’Day
Daniel O’Day · cnbc.com
Images
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blume Ventures is a seed and pre-Series A investment firm headquartered in Mumbai that focuses on early-stage companies in India.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
West Virginia Jobs Investment Trust is a publicly-funded venture capital provider that invests in eligible West Virginia businesses to support job creation and economic development within the state.